Gubra AS (FRA:PI3) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI3 Gubra AS FRA:PI3
78 GF Score
Price €48.02
GF Value €386.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gubra AS FFO per Share?

FFO per Share only applies to REITs.

FRA:PI3
78GF Score
Gubra AS FRA:PI3
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gubra AS (FRA:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of €48.02 is trading 87.6% below its estimated GF Value™ of €386.57. GuruFocus considers Gubra AS to be Possible Value Trap.

Key valuation signals for FRA:PI3:

  • FFO per Share:
  • GF Value™: €386.57 vs. price of €48.02 (87.6% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
78GF Score

Get the complete analysis for FRA:PI3

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.02
Price
€386.57
GF Value